Tim-3 pathway affects NK cell impairment in patients with active tuberculosis

Wang, Feng; Wu, Shiji; Tang, Qing; Huang, Min; Yin, Botao; Huang, Jing; Liu, Weiyong; Mao, Lie; Lu, Yanfang; Sun, Ziyong

doi:10.1016/j.cyto.2015.05.012

Cited by 15 publications

(5 citation statements)

References 41 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differently, we found that the PHA results gradually increased after treatment, especially at 6 months of treatment. This is in accordance with previous studies indicating that host immunity is restored after TB treatment [36][37][38]. The lymphocyte response to PHA stimulation reflects the functional potential of them [39], and the increase of PHA results in T-SPOT assay indicates the restoration of lymphocyte function in TB patients after treatment.…”

Section: Discussionsupporting

confidence: 92%

Using TBAg/PHA Ratio for Monitoring TB Treatment: A Prospective Multicenter Study

Wang

Liu

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

The way to monitor tuberculosis (TB) treatment is extremely lacking in clinical practice. The aim of the study is to assess the role of the TBAg/PHA ratio in the treatment monitoring of TB. TB patients were followed up for 6 months and serial T-SPOT.TB (T-SPOT) assays were performed. In patients with successful treatment outcomes, the ESAT-6 sfc, CFP-10 sfc, and TBAg/PHA ratio all showed a decreased trend after the initiation of treatment. Conversely, PHA sfc showed an increased trend after 2 months of treatment. However, these indicators had moderate performance in distinguishing between before and after 6 months of treatment, and the AUC ranged from 0.702 to 0.839. Notably, the TBAg/PHA ratio in patients without risk factors was of important value in differentiation between before and after treatment. The optimal AUC of TBAg/PHA ratio reached up to 0.890. Patients with unsuccessful treatment outcomes showed persistently high levels of TBAg/PHA ratio. The TBAg/PHA ratio in patients after 6 months of treatment showed a certain potential in distinguishing between patients with successful and unsuccessful treatment outcomes. A further calculation of the TBAg/PHA ratio in T-SPOT assay has potential value in the treatment monitoring of TB, but further confirmation is needed.

show abstract

Section: Discussionsupporting

confidence: 92%

Using TBAg/PHA Ratio for Monitoring TB Treatment: A Prospective Multicenter Study

Wang

Liu

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Lysosome-associated glycoprotein CD107a serves as a marker of degranulation of CD8+ T cells and NK cells (Aktas et al, 2009 ; Shabrish et al, 2016 ). Kumar et al ( 2015 ) and our study Wang et al ( 2015 ) found that CD107a expression on CD8+ T cells and NK cells is significantly diminished in ATB patients, which indicates the impairment of these cells during TB progression. Furthermore, CD25 and HLA-DR are typical immunological markers that reflect T cell activation in response to microbial infection or vaccination (Sava and Toldi, 2016 ; Bajnok and Ivanova, 2017 ).…”

Section: Discussionsupporting

confidence: 59%

“…Many immunological markers are also evaluated for overcoming the problems (Dorhoi and Kaufmann, 2014 ; Hoppe et al, 2016 ). For instance, the expression of activation receptor HLA-DR (Fletcher et al, 2016 ) and immune inhibitory receptors PD-1 and Tim-3 (Blok et al, 2015 ; Wang et al, 2015 ; Jayaraman et al, 2016 ) on CD4+T cells or NK cells are significantly increased in ATB patients. Most existing studies focus on the role of immunological markers in the pathogenesis of TB disease, while evaluating host immune status as a way for ATB diagnosis is rarely concerned (Della Bella et al, 2008 ; Cantini et al, 2016 ; Harries et al, 2016 ; Petruccioli et al, 2016b ).…”

Section: Introductionmentioning

confidence: 99%

Application of ImmunoScore Model for the Differentiation between Active Tuberculosis and Latent Tuberculosis Infection as Well as Monitoring Anti-tuberculosis Therapy

Zhou

Hou

et al. 2017

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

Tuberculosis (TB) is a leading global public health problem. To achieve the end TB strategy, non-invasive markers for diagnosis and treatment monitoring of TB disease are urgently needed, especially in high-endemic countries such as China. Interferon-gamma release assays (IGRAs) and tuberculin skin test (TST), frequently used immunological methods for TB detection, are intrinsically unable to discriminate active tuberculosis (ATB) from latent tuberculosis infection (LTBI). Thus, the specificity of these methods in the diagnosis of ATB is dependent upon the local prevalence of LTBI. The pathogen-detecting methods such as acid-fast staining and culture, all have limitations in clinical application. ImmunoScore (IS) is a new promising prognostic tool which was commonly used in tumor. However, the importance of host immunity has also been demonstrated in TB pathogenesis, which implies the possibility of using IS model for ATB diagnosis and therapy monitoring. In the present study, we focused on the performance of IS model in the differentiation between ATB and LTBI and in treatment monitoring of TB disease. We have totally screened five immunological markers (four non-specific markers and one TB-specific marker) and successfully established IS model by using Lasso logistic regression analysis. As expected, the IS model can effectively distinguish ATB from LTBI (with a sensitivity of 95.7% and a specificity of 92.1%) and also has potential value in the treatment monitoring of TB disease.

show abstract

“…Similarly, increased cytotoxicity of NK cells from chronic Hepatitis B (CHB) patients was also observed when NK cells were treated with the Tim-3 blocking antibody [16]. Another study revealed that blocking Tim-3 pathway also increased NK cell-mediated cytotoxicity in active tuberculosis patients [31]. These studies only evaluated the role of Tim-3 blockade in NK cells from patients with infectious diseases.…”

Section: Discussionmentioning

confidence: 93%

Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma

Huang

Tan

et al. 2015

International Immunopharmacology

172

124

View full text Add to dashboard Cite

Tim-3 pathway affects NK cell impairment in patients with active tuberculosis

Cited by 15 publications

References 41 publications

Using TBAg/PHA Ratio for Monitoring TB Treatment: A Prospective Multicenter Study

Using TBAg/PHA Ratio for Monitoring TB Treatment: A Prospective Multicenter Study

Application of ImmunoScore Model for the Differentiation between Active Tuberculosis and Latent Tuberculosis Infection as Well as Monitoring Anti-tuberculosis Therapy

Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma

Contact Info

Product

Resources

About